0.351

1.21% -0.0043

After Hours: .36 0.009 +2.56%

Bolt Biotherapeutics Inc (BOLT)

Overview News Price History Financials Discussions Forecast

Bolt Biotherapeutics Inc stock is traded at $0.351, with a volume of 35,539. It is down -1.21% in the last 24 hours and down -8.36% over the past month. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Previous Close:

$0.3553

Open:

$0.3607

24h Volume:

35,539

Relative Volume:

0.30

Market Cap:

$14.91M

Revenue:

$7.88M

Net Income/Loss:

$-69.20M

P/E Ratio:

-0.1918

EPS:

-1.83

Net Cash Flow:

$-69.73M

1W Performance:

-9.77%

1M Performance:

-8.36%

6M Performance:

-46.70%

1Y Performance:

-68.66%

1-Day Range:

$0.35

$0.3799

1-Week Range:

$0.3407

$0.41

52-Week Range:

$0.30

$1.335

Bolt Biotherapeutics Inc Stock (BOLT) Company Profile

Name

Bolt Biotherapeutics Inc

Sector

Healthcare (1152)

Industry

Biotechnology (662)

Phone

650-665-9295

Address

900 CHESAPEAKE DRIVE, REDWOOD CITY

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

BOLT's Discussions on Twitter

Compare BOLT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BOLT Bolt Biotherapeutics Inc	0.351	14.91M	7.88M	-69.20M	-69.73M	-1.83
VRTX Vertex Pharmaceuticals Inc	498.86	126.60B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	590.00	64.75B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	639.90	36.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	255.13	31.40B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	102.43	28.98B	2.98B	-717.57M	-264.74M	-2.9987

Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-06-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-02-21	Initiated	Guggenheim	Buy
Mar-02-21	Initiated	Morgan Stanley	Overweight
Mar-02-21	Initiated	SVB Leerink	Outperform
Mar-02-21	Initiated	Stifel	Buy

Bolt Biotherapeutics Inc Stock (BOLT) Latest News

01:49 AM

Bolt Biotherapeutics amends bylaws, adjusts quorum requirement - Investing.com Australia

01:49 AM

Apr 30, 2025

Innovative Advances in Bolt Biotherapeutics (BOLT) Cancer Therap - GuruFocus

Apr 30, 2025

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - The Manila Times

Apr 30, 2025

New Cancer Treatment Breakthrough: Bolt Bio's Dual-Target Therapy Achieves Complete Response in Early Tests - Stock Titan

Apr 30, 2025

Apr 29, 2025

Bolt Biotherapeutics amends bylaws, adjusts quorum requirement By Investing.com - Investing.com India

Apr 29, 2025

Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025

Apr 25, 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Esca - GuruFocus

Apr 25, 2025

Bolt Biotherapeutics reports positive Phase 1 cancer trial results By Investing.com - Investing.com India

Apr 25, 2025

Bolt Biotherapeutics Reports Positive Phase 1 Results for BDC-3042, Demonstrating Safety and Anti-Tumor Activity in Cancer Patients - Nasdaq

Apr 25, 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - The Manila Times

Apr 25, 2025

Breakthrough Cancer Drug Achieves 80% Disease Control: Phase 1 Trial Reveals Promising NSCLC Results - Stock Titan

Apr 25, 2025

Apr 17, 2025

Bolt Biotherapeutics modifies quorum requirements By Investing.com - Investing.com Canada

Apr 17, 2025

Apr 16, 2025

Bolt Biotherapeutics modifies quorum requirements - Investing.com

Apr 16, 2025

Apr 12, 2025

BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - marketscreener.com

Apr 12, 2025

Apr 10, 2025

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 10, 2025

Apr 08, 2025

Sept. 3rd Deadline ALERT: Investors Who Lost More Than $100,000 With Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shares Should Contact the Shareholders Foundation - ACCESS Newswire

Apr 08, 2025

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 08, 2025

Apr 07, 2025

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Bolt Biotherapeutics, Inc. (BOLT) - ACCESS Newswire

Apr 07, 2025

Apr 04, 2025

Bolt Biotherapeutics stock hits 52-week low at $0.38 By Investing.com - Investing.com UK

Apr 04, 2025

Apr 03, 2025

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 03, 2025

Mar 29, 2025

H.C. Wainwright holds Neutral on Bolt Biotherapeutics stock By Investing.com - Investing.com Australia

Mar 26, 2025

H.C. Wainwright holds Neutral on Bolt Biotherapeutics stock - Investing.com India

Mar 26, 2025

Bolt Biotherapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView

Mar 26, 2025